Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ulixacaltamide (PRAX-944) / Praxis Precision Medicines
NCT06087276: Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)	Recruiting	3	600	US	60 mg ulixacaltamide, Placebo	Praxis Precision Medicines	Essential Tremor	09/24	04/25
ACTRN12619001052123: A Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Essential Tremor	Recruiting	2	12			Praxis Precision Medicines, Praxis Precision Medicines Australia, Pty Ltd	Essential Tremor
ACTRN12622000408785: A Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Essential Tremor - Part B	Recruiting	2	12			Praxis Precision Medicines, Praxis Precision Medicines Australia, Pty Ltd	Essential Tremor
NCT05021991: A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor	Completed	2	133	Canada, US	100 mg PRAX-944, 60 mg PRAX-944, Placebo, Flexibly dosed 20 mg to 100 mg PRAX-944	Praxis Precision Medicines	Essential Tremor	02/23	02/24